Liuzhou Chemical Industry (600423.SH) plans to invest approximately 290 million yuan to build a 200,000 tons per year peracetic acid fluidized bed hydrogen peroxide project.
Yuanhua Group (600423.SH) announced that, in order to actively respond to the strategy of promoting high-quality development of listed companies, effectively enhance the company's sustainable operation capability and core competitiveness, and effectively resolve the existing shortcomings such as limited asset scale and weak profitability, after in-depth research and demonstration by the company, it is planned to invest in the construction of a 200,000 tons/year full acid fluidized bed hydrogen peroxide production unit, with a total investment of approximately 290 million yuan and a construction period of 24 months (2 years).
Liuzhou Chemical Industry (600423.SH) announced that, in order to actively respond to the strategy of promoting high-quality development of listed companies, effectively enhance the company's sustainable operation capability and core competitiveness, and resolve the existing development weaknesses such as limited asset scale and weak profitability, the company has conducted in-depth research and demonstration and plans to invest in the construction of a 200,000 tons/year full acid fluidized bed hydrogen peroxide production unit, with a total investment of approximately 290 million yuan and a construction period of 24 months (2 years).
After the completion and production of this investment project, the company's hydrogen peroxide production capacity will increase from 160,000 tons/year to over 360,000 tons/year, directly enhancing the company's main business scale and bringing good project economic benefits to the company to stabilize the basic fundamentals of the listed company. The project adopts advanced production technology, which is conducive to safe production and environmental protection, and is in line with the company's strategic planning for green and low-carbon development.
Related Articles

INSILICO (03696) reached global pipeline authorization and AI drug development cooperation with Roche.

JIANGSU EXPRESS (00177) has announced its performance for 2025, with a net profit attributable to shareholders of approximately RMB 4.594 billion, representing a year-on-year decrease of about 7.13%.

New Stock News | Aqara International Ltd. Submits Application to Hong Kong Stock Exchange
INSILICO (03696) reached global pipeline authorization and AI drug development cooperation with Roche.

JIANGSU EXPRESS (00177) has announced its performance for 2025, with a net profit attributable to shareholders of approximately RMB 4.594 billion, representing a year-on-year decrease of about 7.13%.

New Stock News | Aqara International Ltd. Submits Application to Hong Kong Stock Exchange

RECOMMEND

Chinese Innovative Drug Assets Attract Major Foreign Acquisition, Cooperation Models Diversify
26/03/2026

Four Giants Subscribe As Memory Manufacturer Confirms TWD 78.718 Billion Private Placement For Capacity Expansion
26/03/2026

Year‑On‑Year Surge Exceeding 500%: Hong Kong IPOs Top HKD 100 Billion This Year
26/03/2026


